Anti-IgE therapy versus allergen-specific immunotherapy for food allergy: weighing the pros and cons

Anti-IgE therapy versus allergen-specific immunotherapy for food allergy: weighing the pros and cons

With the recent FDA approval of the anti-IgE biologic, omalizumab, in 2024 for the treatment of food allergy, it is critical to consider the advantages and disadvantages of anti-IgE and allergen-specific immunotherapies (AITs) to help determine optimal patient care. Several AITs have been studied fo...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael D. Kulis, Jessica R. Humphrey, James W. Krempski, Edwin H. Kim, Johanna M. Smeekens
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Immunology
Subjects:
omalizumab
allergy immunotherapy
oral immunotherapy
sublingual immunotherapy
epicutaneous immunotherapy
IgE
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1617153/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items